Clemastine
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a682542 | 
| Routes of administration | Oral | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Bioavailability | 39.2% | 
| Metabolism | Hepatic | 
| Elimination half-life | 21.3 hours | 
| Excretion | Renal | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H26ClNO | 
| Molar mass | 343.90 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Clemastine, also known as meclastin, is a first-generation H1 histamine antagonist (antihistamine) with anticholinergic properties (drying) and sedative side effects. Like all first-generation antihistamines, it is sedating.
Patented in 1960, it came into medical use in 1967.